Search PubMed⌕ Search

Biomedical subjects

G Vorberg

Publications and source records attributed to G Vorberg.

At least 19 recordsLinked to original sources
PubMed1990

Therapy with garlic: results of a placebo-controlled, double-blind study.

A double-blind study of 40 hypercholesterolaemic out-patients was carried out over a period of four months to examine the effects of a garlic powder preparation*. The drug group received 900 mg garlic powder per day, equivalent to 2,700 mg of fresh garlic. During the therapy, the drug group showed significantly lower total cholesterol, triglycerides and blood pressure than those of the placebo group. In addition, results of a self-evaluation questionnaire indicated that patients in the drug group had a greater feeling of 'well-being'.

Affect↗
PubMed1990

A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis.

This double-blind, parallel, controlled and randomized trial compares the clinical efficacy and tolerance of a new NSAID (pro-drug of piroxicam), droxicam, at the dose of 20 mg/day against that of piroxicam at the same dose. The comparison is drawn after the administration to 30 patients with spinal osteoarthritis during 8 weeks after a single-blind placebo-period run-in of 7 days. Results show that both drugs improve, with statistical significance, all parameters evaluated (pain intensity, morning stiffness, nocturnal pain, pain after getting up and after 30 min standing, difficulty in daily living, frequency of pain exacerbations and the ability to do several daily activities). No statistically significant differences were found between groups. Only one case in the droxicam group and two in the piroxicam group reported subjective complaints of mild intensity that did not require additional treatment or interruption of the study.

Administration, Oral↗
PubMed1980

[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].

Efficacy and tolerance of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, Duolip) was investigated in 100 patients under practitioner conditions, out of whom 50 patients received daily 500 mg (2 x 1 capsule etofylline clofibrate and 50 patients daily 750 mg (3 x 1 capsule) over a therapeutic period of 8 weeks each. The whole group consisted of patients of type IIa, IIb and IV. The effect on blood lipids was determined in the parameters cholesterol, triglycerides and total-beta-lipoproteins. In patients of type II high and significant reduction of cholesterol and of total-beta-lipoproteins (27%) were found, in type IV especially significant reductions of triglycerides and total-beta-lipoproteins of 37 and 24%, resp. The rate of responders in type II was between 50 and 100%. Common blood parameters of tolerance did not show remarkable alterations. Unspecific gastrointestinal side effects were only observed in 3 patients. For the therapy of hypolipoproteinaemia etofylline clofibrate was established as a highly active, low-dosed drug.

Clofibrate↗
PubMed1976

[Effective therapy of chronic arterial circulatory disorders with Nico-Padutin forte (author's transl)].

Over a period of 6 weeks, 90 patients of both sexes (principally male) aged from 38 to 81 years were treated with Nico-Padutin forte (BAY b 7979; 40 units kallikrein + 300 mg inositol nicotinate) for chronic arterial disorders of the lower extremities. Positive therapeutic results were obtained in 82 cases (91.2%) with a dosage of 1 tablet 3 times daily. The effect of the treatment was assessed by the cardinal symptom of intermittent claudication. The walking test was used as the clinical parameter. The significant lowering of the raised blood lipid levels (both in the cholesterol and triglyceride ranges) by treatment with BAY b 7979 is to be considered relevant in the importance of hyperlipidemia as a risk factor in arterial vascular diseases. As long as the controindications (acute myocardial infarction, acute hemorrhages) were given attention, tolerance was outstanding.

Adult↗